Company: HURA
Filing Date: 2025-05-06
Form Type: S-4/A
Source: 0001193125-25-113920
Chunk: 615

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-05-06
Form: S-4/A
Chunk 615
---
asured at fair value at each reporting period with the changes in fair value recorded in the statement of operations.

Change in Fair Value Measurement of Notes Payable

Change in fair value of notes payable relates to the remeasurement of the notes payable that Kineta elected to account for under the fair value option. Until settlement, these notes payable are remeasured at fair value at each reporting period with the changes in fair value recorded in the statement of operations.

Other (Expense) Income, Net

Other (expense) income, net consists of items that are of a non-recurring nature and primarily relate to items that are immaterial.

Net (Loss) Income Attributable to Noncontrolling Interest

Net (loss) income attributable to noncontrolling interest reflects investors’ share of net (loss) income in Kineta’s majority owned subsidiary.**

#### Segment Reporting
Kineta operates as a single reportable segment, which is primarily engaged in the development of next-generation immunotherapies. Kineta has concluded that its President is the chief operating decision maker (“CODM”) for the year ended December 31, 2024 and its former CEO and President together were the CODM for the year ended December 31, 2023. The CODM reviews the Company’s performance and allocates resources on a consolidated basis.

Kineta did not generate revenue for the year ended December 31, 2024 and generated license and collaboration revenue from one customer located in the United States for the year ended December 31, 2023.

<div align='center'>396</div>

Results of Operations Comparison of the Years Ended December 31, 2024 and 2023 The following table summarizes Kineta’s results of operations for the periods presented:

| Revenues:                                                 |     | Years Ended December 31, 
 2024                     
 (in thousands)           |         |   |     | 2023 |         |   |     | Change |        |   |
|:----------------------------------------------------------|:----|:-------------------------|--------:|:--|:----|:-----|--------:|:--|:----|:-------|-------:|:--|
| Licensing revenues                                        |     | $                        |       — |   |     | $    |   5,000 |   |     | $      | (5,000 | ) |
| Collaboration revenues                                    |     |                          |       — |   |     |      |     442 |   |     |        |